Category Regulatory

Biopharma

Vividion Publishes Preclinical Data in Science on Novel RAS-PI3K Inhibitors Blocking Tumor Growth

Vividion Publishes Groundbreaking Science Study on Covalent RAS-PI3Kα Inhibitors That Halt Tumor Growth Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and wholly owned, independently operated subsidiary of Bayer AG, has announced the publication of a pivotal manuscript in Science…

Read MoreVividion Publishes Preclinical Data in Science on Novel RAS-PI3K Inhibitors Blocking Tumor Growth

Perceptive Imaging Appoints Doug Fulling as CEO to Lead Growth and Innovation

Perceptive Imaging Appoints Doug Fulling as CEO to Lead Global Growth, Enhance Services, and Drive Innovation in Clinical Trial Imaging Perceptive Imaging (“Perceptive” or “the Company”), a global leader in clinical trial imaging services for the pharmaceutical and biotech industries,…

Read MorePerceptive Imaging Appoints Doug Fulling as CEO to Lead Growth and Innovation

Thermo Fisher Launches Molecular Microscope System for Lung Transplant Rejection Detection

Thermo Fisher Scientific Launches Molecular Microscope Diagnostic System to Transform Lung Transplant Rejection Detection and Management Thermo Fisher Scientific Inc., the global leader in serving science, has unveiled an innovative laboratory-developed test (LDT) that aims to revolutionize the detection and…

Read MoreThermo Fisher Launches Molecular Microscope System for Lung Transplant Rejection Detection
Cancer

Kairos Pharma Reports Positive Phase 2 Prostate Cancer Data at ESMO 2025

Kairos Pharma to Present Promising Phase 2 Prostate Cancer Data Highlighting Carotuximab’s Potential to Overcome Hormone Therapy Resistance at ESMO 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics that address treatment…

Read MoreKairos Pharma Reports Positive Phase 2 Prostate Cancer Data at ESMO 2025

Bimiralisib Topical PI3K/mTOR Inhibitor Achieves 92% Clearance in Actinic Keratosis Study

Bimiralisib Topical PI3K/mTOR Inhibitor Demonstrates Up to 92% Clearance and Excellent Tolerability in Phase 2 Actinic Keratosis Trial Torqur AG, a clinical-stage biopharmaceutical company and a subsidiary of the Swiss Rockets AG incubator, has announced highly encouraging results from its…

Read MoreBimiralisib Topical PI3K/mTOR Inhibitor Achieves 92% Clearance in Actinic Keratosis Study

Lymphoma ADC Market Outlook 2030: Pipeline, Patents, Prices & Clinical Trials

Global Lymphoma Antibody Drug Conjugates Market 2030: Pipeline, Patents, Prices, Approved Sales, and Clinical Trial Insights Lymphoma Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030”, providing an in-depth analysis of the evolving landscape…

Read MoreLymphoma ADC Market Outlook 2030: Pipeline, Patents, Prices & Clinical Trials

HELIOS-B Phase 3: Vutrisiran Shows Fewer GI Events in ATTR-CM Patients

Alnylam Pharmaceuticals Reports HELIOS-B Phase 3 Findings: Vutrisiran Reduces Gastrointestinal Events in ATTR-CM Patients Alnylam Pharmaceuticals, Inc. , a global leader in RNA interference (RNAi) therapeutics, today unveiled new analyses from the HELIOS-B Phase 3 study evaluating AMVUTTRA® (vutrisiran). Vutrisiran…

Read MoreHELIOS-B Phase 3: Vutrisiran Shows Fewer GI Events in ATTR-CM Patients
AOP Health

International Day of Older Persons: AOP Health Raises Awareness of the Hidden Burden of Venous Leg Ulcers

International Day of Older Persons: AOP Health Brings Urgent Attention to the Silent Burden of Venous Leg Ulcers Every year on October 1, the world observes the United Nations’ International Day of Older Persons, a moment dedicated to honoring the…

Read MoreInternational Day of Older Persons: AOP Health Raises Awareness of the Hidden Burden of Venous Leg Ulcers

Quince Therapeutics Publishes eDSP PopPK Modeling Study in CPT: PSP

Quince Therapeutics Publishes Advanced Population PK Modeling Study of eDSP in Pediatric Ataxia-Telangiectasia Patients in CPT: Pharmacometrics & Systems Pharmacology Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company pioneering patient-specific therapies for rare diseases, has announced the publication of…

Read MoreQuince Therapeutics Publishes eDSP PopPK Modeling Study in CPT: PSP